This inventor holds 1 USPTO granted patent. Top assignees: Aum Lifetech, Inc., University of Pennsylvania. Active years: 2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:

Years Active: 2024
Title: Innovations of Manoj Kumar Mishra in Duchenne Muscular Dystrophy Therapy.
Introduction
Manoj Kumar Mishra is an accomplished inventor based in Philadelphia, PA. He has made significant contributions to the field of medical research, particularly in the treatment of Duchenne Muscular Dystrophy (DMD). His innovative work focuses on enhancing utrophin protein production, which is crucial for addressing myopathies.
Latest Patents
Mishra holds a patent for his invention titled "2'F-ANA-LET7 mediated utrophin upregulation for DMD therapy." This invention relates to compositions and methods designed to enhance or upregulate utrophin protein production. Specifically, it involves the use of oligonucleotides to block the binding of let-7c miRNA to the utrophin mRNA 3' untranslated region (UTR). This innovative approach aims to provide new therapeutic options for individuals suffering from DMD.
Career Highlights
Throughout his career, Manoj Kumar Mishra has worked with notable institutions, including the University of Pennsylvania and Aum Lifetech, Inc. His experience in these organizations has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Mishra has collaborated with esteemed colleagues such as Tejvir S Khurana and Veenu Aishwarya. These partnerships have further enriched his research and have played a vital role in advancing the understanding and treatment of muscular dystrophies.
Conclusion
Manoj Kumar Mishra's innovative work in the field of DMD therapy exemplifies the impact of research and invention on medical science. His contributions are paving the way for new treatment options that could significantly improve the quality of life for those affected by this condition.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile